STAT+: FDA rejection is a reality check on agency rhetoric
Stat News • 2/26/2026
Summary
Sarepta CEO has stepped down following the rejection of an experimental cell therapy by the FDA. The news highlights a reality check regarding the agency's rhetoric in the biotech sector.
Advertisement
Lindy Score Breakdown (V4.2)
1h
Age
1
Sources
from cluster
1
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier99% (0.5^1/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Related Stories
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more
Stat News • Today
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
Stat News • Today
STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
Stat News • 2 days ago
STAT+: An AI startup floats FDA deregulation, using an obscure backdoor
Stat News • 2 days ago
STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect
Stat News • Today
STAT+: How Mayo Clinic’s patients are helping Merck train its AI
Stat News • 1 day ago
STAT+: Rare disease advocates fume over FDA’s mixed signals
Stat News • Today
Opinion: STAT+: Optum CMO: Doctors must take responsibility for patient outcomes
Stat News • 2 days ago
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications
Stat News • 2 days ago
STAT+: Novo reports ‘triple G’ obesity drug study results
Stat News • 2 days ago